aTyr Pharma Q2 2023: cash $112M, R&D $9.8M; Phase 3 EFZO-FIT enrolling globally

aTYR PHARMA INC

2023-Q2 EPS reported -$0.50

Cash and investments $112.0M as of June 30, 2023; company expects cash runway into 2026.
R&D expenses $9.8M, G&A $3.7M in Q2 2023.
Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolling up to 264 subjects globally.
Phase 2 EFZO-CONNECT study in SSc-ILD expected to start Q3 2023, enrolling 25 patients.
Received European Commission orphan drug designation for efzofitimod in systemic sclerosis.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

aTYR PHARMA INC reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended June 30, 2023.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

aTYR PHARMA INC filing history →

Source: SEC EDGAR

accession 0000950170-23-040581

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.